GRAIL Announces First Participant Enrolled in REACH Study Evaluating Clinical Impact of Galleri® Multi-Cancer Early Detection (MCED) Test in the Medicare Population

Community Health Network Has Begun Enrollment of the Prospective, Multi-Center Study to Assess the Real-World Clinical Impact of Galleri^® in Addition to Currently Recommended Cancer Screenings

Study Enrollment Includes Focus on Diverse and Underrepresented Populations

Costs of Galleri and Related Items and Services for Study Participants Will be Covered by Medicare

Excerpt from the Press Release:

MENLO PARK, Calif., July 18, 2024 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first participant has been enrolled in the REACH/Galleri-Medicare study at Community Health Network, a leading integrated healthcare system in central Indiana with more than 200 sites of care. With age being the most significant risk factor for cancer, Medicare beneficiaries face a critical unmet need for early cancer detection.

“We are excited about the REACH study and the work that GRAIL is doing to detect cancer early when it is more likely to be successfully treated,” said Patrick McGill, M.D., Executive Vice President, Chief Transformation Officer and Principal Investigator of the REACH study at Community Health Network. “As a health network committed to exceptional care for patients, it was important for Community Health Network to participate in the REACH study. We really want to expand upon and understand the real-world evidence of the Galleri^® test. Since the focus is on underrepresented minorities, we felt strongly that this was an opportunity to offer the test as part of the REACH study to many of the people who are traditionally or historically underrepresented in clinical studies. We feel strongly about the science of the test and the potential it holds to improve health outcomes for our Medicare patients.”

The Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare) study is a first-of-its-kind real-world evidence study designed to further evaluate the clinical impact of the Galleri multi-cancer early detection (MCED) test in Medicare beneficiaries. The study aims to enroll participants with a specific focus on inclusion of historically underrepresented communities, including seniors and people across diverse racial and ethnic minority groups, as well as socioeconomically disadvantaged and rural populations.

Click the button below to read the entire Press Release:

Continue Reading The Press Release